BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory front for July 1, 2020

July 1, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Indivior, Reckitt Benckiser, Glenmark, Apotex, Intercept, Teva.
Read More

Regulatory actions for July 1, 2020

July 1, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bavarian, Blueprint, EMD, Golden, Hangzhou Yuyuan, Isa, Janssen, Medicinova, Mezzion, Pfizer, Revive, Rhythm, Scpharmaceuticals, Sun, TC, Obseva, Ultragenyx, Y-mabs.
Read More

Other news to note for July 1, 2020

July 1, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advanced Biodesign, Aligos, Avadel, Binx Health, Bioinvent, Boehringer Ingelheim, Canagen, Celsius, Crestone, Dr. Reddy’s, Eisai, Emollivet, Epicentrx, Exela, Fujifilm, Foresight, G1, Genix, Ginkgo Bioworks, Leo, Liminal, Lipidor, Myneo, Pfizer, Prometic, Quralis, Repurpose.AI, Revolution Medicines, Sciclone, Sherlock Biosciences, Sumitomo Dainippon, Therapix, Thinkcyte, Van Heron Labs.
Read More

In the clinic for July 1, 2020

July 1, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akero, Anavex, Biondvax, Biontech, Context, Corcept, Daiichi, Durect, Eyenovia, Ipsen, Matinas, Oncolys, Pfizer, Polypid, Revance, Timber, Vasopharm.
Read More
COVID-19 vaccine vials behind U.S. capitol building

FDA posts guidance for COVID-19 vaccines as Hahn assures FDA will cut no corners

June 30, 2020
By Mark McCarty
The push for a vaccine for the COVID-19 pandemic may have no parallel in pharmaceutical history, and FDA commissioner Stephen Hahn vowed in a Senate hearing that the agency will rely on the agency’s traditional standards for scientific evidence in premarket reviews of those vaccines.
Read More

Regulatory actions for June 30, 2020

June 30, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aerus, Ancora Heart, Corelink, Endra Life Sciences, Illuminoss Medical, Kardium, Livsmed, Qure.ai, Seegene.
Read More

Other news to note for June 30, 2020

June 30, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Activ Surgical, Alberta Health Services, Ambu, Ascom, Biocorp, Blueprint Medicines, Ci Security, Coeus Consulting, C-Rad, Cylera, Dermtech, Endbraincancer Initiative, Flir Systems, Forest Devices, Fuel Medical Group, Gt Medical Technologies, Helferapp, Humana, Innominds Software, Ion Beam Applications, Labcorp, Leica Microsystems, Luminex, Medigate, Mindmaze, Novavision, Mirador Global, Mobidiag, Ordr, Oxitone Medical, Plano, Pra Health Sciences, Pressure Biosciences, Proscia, Protxx, Quest Diagnostics, Roche, Royal Philips, Santen Pharmaceutical, Sauber Engineering, Stryker, Trialjectory, Twist Bioscience, Vericel, Vycor Medical, Walmart, Wright Medical Group.
Read More
Financial chart, upward arrow

Public biopharmaceutical companies post strong gains in second quarter

June 30, 2020
By Peter Winter
The share prices of blue-chip biopharmaceutical companies closed out the month on a high note to contribute to their stellar collective performance during the second quarter, with the BioWorld Biopharmaceutical index increasing almost 20%.
Read More

Regulatory front for June 30, 2020

June 30, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory actions for June 30, 2020

June 30, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alterity, Ardelyx, Astrazeneca, Bioinvent, Mediwound, Merck, Nuvox, Oncopeptides, Oncternal, Osmotica, Prestige, Sparingvision, Synthetic Biologics, Vericel, Verrica.
Read More
Previous 1 2 … 424 425 426 427 428 429 430 431 432 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • Liver with hepatitis viruses, blood cells

    Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

    BioWorld
    GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing